Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development

Cancer Genetics and Cytogenetics

Volumn 186, Issue 1, 2008, Pages 6-11

  Ohyashiki, Kazuma ^a   Kodama, Atsushi ^a   Ohyashiki, Junko H ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; JAK2 GENE; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; PRIORITY JOURNAL; THROMBOCYTHEMIA;

ADULT; AGED; AMINO ACID SUBSTITUTION; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 9; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOFIBROSIS; POINT MUTATION; SPECTRAL KARYOTYPING; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 50949117772     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.04.021     Document Type: Article

References (21)

1. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434 (2005) 1144-1145
2. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., and Green A.R. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
3. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 779-790
4. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Fröhling S., Döhner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J., and Gilliland D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
5. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., and Zhao Z.J. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 280 (2005) 788-792
6. Goldman J.M. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 352 (2005) 1744-1746
7. Tiedt R., Hao-Shen H., Sobas M.A., Looser R., Dirnhofer S., Schwaller J., and Skoda R.C. Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111 (2008) 3931-3940
8. Shide K., Shimoda H.K., Kumano T., Karube K., Kameda T., Takenaka K., Oku S., Abe H., Katayose K.S., Kubuki Y., Kusumoto K., Hasuike S., Tahara Y., Nagata K., Matsuda T., Ohshima K., Harada M., and Shimoda K. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 22 (2008) 87-95
9. V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 21 (2007) 1097-1099
10. V617F mutation: a single institutional study in Japan. Leukemia 21 (2007) 1570-1571
11. Imbert M., Pierre R., Thiele J., Vardiman J.W., Brunning R.D., and Flandrin G. Essential thrombocythemia. In: Jaffe E.S., Harris N.L., Stein H., and Varidiman J.W. (Eds). World Health Organization of Tumours: Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues (2001), IARC Press, Lyon 39-41
12. V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection. Cancer Genet Cytogenet 179 (2007) 19-24
13. Hsiao H.H., Ito Y., Sashida G., Ohyashiki J.H., and Ohyashiki K. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. Leuk Res 29 (2005) 1247-1252
14. Borgström G.H., Knuutila S., Ruutu T., Pakkala A., Lahtinen R., and de la Chapelle A. Abnormalities of chromosome 13 in myelofibrosis. Scand J Haematol 33 (1984) 15-21
15. Djordjevic V., Dencic-Fekete M., Jovanovic J., Bizic S., Jankovic G., Bogdanovic A., Cemerikic-Martinovic V., and Gotic M. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients. Cancer Genet Cytogenet 173 (2007) 57-62
16. Andrieux J., Demory J.L., Caulier M.T., Agape P., Wetterwald M., Bauters F., and Laï J.L. Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet Cytogenet 140 (2003) 118-123
17. Diez-Martin J.L., Graham D.L., Petitt R.M., and Dewald G.W. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 66 (1991) 287-299
18. Rege-Cambrin G., Mecucci C., Tricot G., Michaux J.L., Louwagie A., Van Hove W., Francart H., and Van den Berghe H. A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 25 (1987) 233-245
19. Zamora L., Espinet B., Florensa L., Besses C., Woessner S., Serrano S., and Solé F. Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients?. Cancer Genet Cytogenet 151 (2004) 139-145
20. Larsen T.S., Hasselbalch H.C., Pallisgaard N., and Kerndrup G.B. A der(18) t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis. Cancer Genet Cytogenet 172 (2007) 107-112
21. Bacher U., Haferlach T., and Schoch C. Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders. Cancer Genet Cytogenet 160 (2005) 179-183